VA-REGULA
6.8.2024 08:01:33 CEST | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, has released new findings from its study “The New Imperative: Digital IDs,” which unveil how companies worldwide assess their revenue transformation after digital ID implementation. These findings also highlight the use cases where the digital ID adoption will have the most notable effect.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240805603877/en/
Regula's study uncovers how companies globally evaluate revenue transformation post-digital ID implementation, with an overwhelmingly positive outlook. (Graphic: Regula)
Forrester Consulting, commissioned by Regula to conduct “The New Imperative: Digital IDs” study, underlines that most respondents, 89%, anticipate a positive impact on revenue from the adoption of digital IDs. Specifically, 32% of businesses anticipate a 20%-29% rise in revenue, 23% foresee a 10%-19% increase, 16% predict a boost of over 30%, and 18% expect up to a 10% growth.
Interestingly, the Middle East seems to be more optimistic about adopting digital IDs. Only 4% of respondents in this region think that there will be no significant change in revenue, which is much lower than the global rate (10%) or the one in Europe, where 13% of businesses do not expect any change.
The most promising areas
“The New Imperative: Digital IDs” study indicates that the benefits from digital ID implementation will be most noticeable and yield the fastest results in the following top five use cases:
- online financial transactions (46% of respondents globally);
- online account opening (38%);
- eCommerce transactions (33%);
- eGovernment services (32%);
- remote customer onboarding (31%).
The Forrester Consulting study underlines: “These results highlight a significant expectation that digital IDs will enhance efficiency, security, and user experience in sectors where identity verification plays a crucial role in transaction security and customer trust.”
Regional Differences
For the region of North America, the most significant effect is expected to be experienced with online financial transactions (51%), online account opening (39%), remote customer onboarding (36%), and eCommerce transactions (35%). All of these rates are higher than the global. Interestingly, the region is rather more inclined to enhance age verification through digital IDs, with 21% expecting to see improvements in this use case (globally, this rate is 19%, and in the Middle East it is 14%).
In Europe, businesses share the global expectations. Thus, 44% anticipate seeing positive changes in online financial transactions, 38% – in online account opening, 36% – in eGovernment services, 30% – in remote customer onboarding, and 29% – in mobile device access. Europe seems to be more determined to improve eGovernment services: 36% of respondents here (compared to 32% globally) expect to benefit from adopting digital IDs.
In the Middle East, the study respondents express their expectations to see improvements in online financial transactions (44%) and online account opening (35%), though these rates are slightly lower than global. More than the other regions, the Middle East expects to see positive changes in workplace access and remote work (30%, compared to 25% global and 24% in Europe and North America), and healthcare services access (26% compared to 15% global and 9% in Europe).
“Businesses are shifting their approach to identity verification. Once merely a legal requirement or a commodity, it has now become a technological advancement and a strategic imperative. Our study shows that companies worldwide see the transformative potential of digital IDs to boost revenue, enhance security, and improve user experience. As we innovate and deliver advanced identity verification solutions, we are dedicated to helping businesses unlock these benefits and thrive in the digital era,” says Ihar Kliashchou, Chief Technology Officer at Regula.
If you are interested in getting more insights from the study, “The New Imperative: Digital IDs,” please download a complimentary copy from the Regula website.
Additional resources:
- 42% of companies globally are ready to implement Digital ID
- Digital IDs are not going to replace physical documents
- Regional expectations for digital ID fraud reduction
- EU Digital Identity Wallet: Exploring Its Current Potential
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240805603877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
